Cogent Biosciences COGT
$26.72 −$1.03 (-3.70%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $27.20 +1.82%
Open$27.26
Prev close$27.74
Day range$26.62 – $27.83
Volume2.13M
Market cap$4.65B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$117.18M-40.6% YoY
Net profit-$111.43M-37.7% YoY
Diluted EPS-$0.59-18.0% YoY
Free cash flow-$80.90M-25.7% YoY
Operating cash flow-$80.79M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-126.2%
Return on assets-64.8%
Return on invested capital-90.5%
Current ratio10.99
Liabilities / assets38.0%
Cash & investments$791.13M
Total debt$242.64M
Net cash (debt)$548.49M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $117.18M | $102.64M | $103.61M | $333.36M | $99.49M |
| Selling and Admin Expenses | $42.09M | $31.83M | $28.24M | $63.58M | $23.93M |
| -General & Admin Expense | $42.09M | $31.83M | $28.24M | $63.58M | $23.93M |
| Research & Development | $75.10M | $70.81M | $75.37M | $269.78M | $75.56M |
| Operating Profit | -$117.18M | -$102.64M | -$103.61M | -$333.36M | -$99.49M |
| Net Non-Operating Interest Income (Expense) | $5.81M | $6.24M | $6.40M | $11.63M | $4.19M |
| Non-Operating Interest Income | $7.05M | $7.46M | $7.61M | $14.69M | $5.48M |
| Non-Operating Interest Expense | $1.24M | $1.22M | $1.21M | $3.06M | $1.29M |
| Other Income (Expense) | -$51,000.00 | -$11,000.00 | -$140,000.00 | -$7.20M | -$7.19M |
| Other Non-Operating Income (Expenses) | -$51,000.00 | -$11,000.00 | -$140,000.00 | -$20,000.00 | -$6,000.00 |
| Pretax Profit | -$111.43M | -$96.41M | -$97.35M | -$328.94M | -$102.49M |
| Net Profit | -$111.43M | -$96.41M | -$97.35M | -$328.94M | -$102.49M |
| Profit from Continuing Operations | -$111.43M | -$96.41M | -$97.35M | -$328.94M | -$102.49M |
| Net Income to Parent Company | -$111.43M | -$96.41M | -$97.35M | -$328.94M | -$102.49M |
| Net Income to Common Stockholders | -$111.43M | -$96.41M | -$97.35M | -$328.94M | -$102.49M |
| Basic EPS | -$0.59 | -$0.52 | -$0.53 | -$2.16 | -$0.64 |
| Diluted EPS | -$0.59 | -$0.52 | -$0.53 | -$2.16 | -$0.64 |
| Special Income (Charges) | – | – | – | -$7.18M | – |
| -Less:Other Special Charges | – | – | – | $7.18M | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $832.14M | $834.55M | $903.01M | $937.61M | $937.61M |
| Total Current Assets | $803.58M | $804.82M | $877.80M | $910.36M | $910.36M |
| Cash and Cash Equivalents & Short-Term Investments | $791.13M | $792.30M | $866.38M | $900.77M | $900.77M |
| -Cash and Cash Equivalents | $217.46M | $181.17M | $241.21M | $312.01M | $312.01M |
| -Short Term Investments | $573.67M | $611.13M | $625.17M | $588.75M | $588.75M |
| Other Current Assets | $12.45M | $12.52M | $11.43M | $9.59M | $9.59M |
| Total Non-Current Assets | $28.56M | $29.73M | $25.20M | $27.25M | $27.25M |
| Net PPE | $26.23M | $27.37M | $22.85M | $23.54M | $23.54M |
| -Gross PPE | $26.23M | $27.37M | $22.85M | $32.21M | $32.21M |
| Other Non-Current Assets | $2.33M | $2.36M | $2.36M | $3.72M | $3.72M |
| Total Liabilities | $315.88M | $302.16M | $295.31M | $301.24M | $301.24M |
| Total Current Liabilities | $73.12M | $59.30M | $57.98M | $63.95M | $63.95M |
| Payables | $5.94M | $7.49M | $13.74M | $9.50M | $9.50M |
| -Accounts Payable | $5.94M | $7.49M | $13.74M | $9.50M | $9.50M |
| Current Accrued Expenses | $48.09M | $36.50M | $34.80M | $30.42M | $30.42M |
| Short-Term Debt and Capital Lease Obligation | $1.58M | $1.49M | $1.38M | $1.55M | $1.55M |
| -Current Capital Lease Obligation | $1.58M | $1.49M | $1.38M | $1.55M | $1.55M |
| Other Current Liabilities | $2.34M | $1.32M | $1.85M | $6.75M | $6.75M |
| Total Non-Current Liabilities | $242.77M | $242.86M | $237.33M | $237.28M | $237.28M |
| Long Term Debt and Capital Lease Obligation | $242.64M | $242.77M | $237.27M | $237.25M | $237.25M |
| -Long Term Debt | $223.74M | $223.46M | $223.17M | $222.90M | $222.90M |
| -Long Term Capital Lease Obligation | $18.90M | $19.32M | $14.10M | $14.36M | $14.36M |
| Other Non-Current Liabilities | $123,000.00 | $90,000.00 | $62,000.00 | $33,000.00 | $33,000.00 |
| Total Equity | $516.26M | $532.39M | $607.69M | $636.37M | $636.37M |
| Stockholders' Equity | $516.26M | $532.39M | $607.69M | $636.37M | $636.37M |
| Capital Stock | $64.93M | $64.92M | $64.92M | $89.55M | $89.55M |
| -Common Stock | $174,000.00 | $171,000.00 | $171,000.00 | $161,000.00 | $161,000.00 |
| -Preferred Stock | $64.75M | $64.75M | $64.75M | $89.39M | $89.39M |
| Additional Paid-In Capital | $1.95B | $1.85B | $1.83B | $1.73B | $1.73B |
| Retained Earnings | -$1.49B | -$1.38B | -$1.29B | -$1.19B | -$1.19B |
| Gains/Losses Not Affecting Retained Earnings | -$717,000.00 | -$770,000.00 | -$415,000.00 | $355,000.00 | $355,000.00 |
| -Accumulated Depreciation | – | – | – | -$8.68M | -$8.68M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$80.79M | -$77.27M | -$86.88M | -$264.44M | -$79.11M |
| Net cash flow from continuing operations | -$80.79M | -$77.27M | -$86.88M | -$264.44M | -$79.11M |
| Net Income from Continuing Operations | -$111.43M | -$96.41M | -$97.35M | -$328.94M | -$102.49M |
| Gain/Loss from Continuing Operations | $0.00 | -$1,000.00 | $135,000.00 | $7.18M | – |
| Depreciation & Depletion & Amortization | $1.25M | $1.37M | $1.16M | $4.58M | $1.14M |
| Other Non-Cash Items | $287,000.00 | $284,000.00 | $278,000.00 | $601,000.00 | $238,000.00 |
| Change in Working Capital | $12.14M | $1.34M | -$6.83M | $8.01M | $132,000.00 |
| -Change in Prepaid Assets | -$1.32M | $297,000.00 | -$1.84M | -$195,000.00 | -$3.24M |
| -Change in Payables and Accrued Expense | $13.73M | $1.36M | -$5.96M | $8.18M | $2.58M |
| -Change in Other Current Assets | $26,000.00 | $1,000.00 | $1.36M | $1.56M | $1.19M |
| -Change in Other Current Liabilities | -$295,000.00 | -$323,000.00 | -$393,000.00 | -$1.53M | -$394,000.00 |
| Net cash flow from investing | $37.31M | $14.28M | -$36.46M | -$399.53M | -$322.77M |
| Net Cash Flow from Continuing Investing Activities | $37.31M | $14.28M | -$36.46M | -$399.53M | -$322.77M |
| Net PPE Purchase and Sale | -$108,000.00 | -$370,000.00 | -$449,000.00 | -$1.55M | -$811,000.00 |
| Net Investment Purchase and Sale | $37.42M | $14.65M | -$36.01M | -$397.97M | -$321.96M |
| Financing Cash Flow | $79.76M | $2.96M | $52.54M | $878.23M | $588.67M |
| Net Cash Flow from Continuing Financing Activities | $79.76M | $2.96M | $52.54M | $878.23M | $588.67M |
| Net Issuance Payments Of Debt | $0.00 | – | – | $217.76M | $168.47M |
| Net Common Stock Issuance | $71.80M | $0.00 | $45.71M | $159.32M | -$80.72M |
| Proceeds from Stock Option Exercised | $7.96M | $2.96M | $6.82M | $552.67M | $550.14M |
| Ending Cash Balance | $217.88M | $181.59M | $241.62M | $312.43M | $312.43M |
| Net Change in Cash | $36.29M | -$60.04M | -$70.80M | $214.26M | $186.80M |
| Beginning Cash Balance | $181.59M | $241.62M | $312.43M | $98.17M | $125.63M |
| Free Cash Flow | -$80.90M | -$77.64M | -$87.33M | -$266.00M | -$79.92M |
| Net Other Financing Charges | – | – | – | -$51.52M | -$49.21M |
No comments yet — be the first to weigh in on COGT.
Sign in to join the discussion.